Tamoxifen inhibits colorectal cancer metastases in the liver: A study in a murine model

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 5, 1998, Pages 521-527

  Kuruppu, Darshini ^a   Christophi, Chris ^a   Bertram, John F ^b   O'Brien, Paul E ^a  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Colorectal cancer; Intrasplenic model; Metastases; Stereology; Tamoxifen

Indexed keywords

TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEREOLOGY; SURVIVAL RATE; TUMOR GROWTH;

EID: 0031807482     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00680.x     Document Type: Article

References (36)

1. World health statistics annual. Geneve: World Health Organization, 1996; B702-3.
2. Scheele J, Stang R, Hofmann AA, Paul M. Resection of colorectal liver metastases. World J. Surg. 1995; 19: 59-71.
3. Vahrmeijer AL, Van Dierendonck JH, Van deVelde CJH. Treatment of colorectal cancer metastases confined to the liver. Eur. J. Cancer 1995; 31A: 1238-42.
4. Rossi S, Di Stasi M, Buscarini E. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am. J. Roentgenol. 1996; 167: 759-68.
5. Folkman J. The role of angiogenesis in tumour growth. Cancer Biol. 1992; 3: 65-71.
6. Fidler IJ. Critical factors in the biology of human cancer metastasis. Am. Surg. 1995; 61: 1065-6.
7. Nicolson GL. Autocrine and paracrine growth mechanisms in cancer progression and metastasis. In: Bertino JR, ed. Encyclopedia of cancer. CA: Academic press, 1996; 112-24.
8. Auerbach WA, Auerbach RA. Angiogenesis inhibition: A review. Pharmacol. Ther. 1994; 63: 265-311.
9. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res. 1993; 53: 533-5.
10. Jordan VC.The role of tamoxifen in the treatment and prevention of breast cancer. Curr. Probl. Cancer 1992; 16: 132-76.
11. Farinati F, De Maria N, Fornasiero A et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig. Dis. Sci. 1992; 37: 659-62.
12. Wadu T, Nishiyama K, Maeda M et al. Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma. Anticancer Res. 1995; 15: 1581-4.
13. Sing S, Paraskeva C, Gallimore PH, Sheppard MC, Langman JS. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res. 1994; 14: 1037-42.
14. Kuruppu D, Christophi C, Bertram JF, O'Brien PE. Characterisation of an animal model of hepatic metastasis. J. Gastroenterol. Hepatol. 1996; 11: 26-32.
15. Sutherland RL, Murphy LC. Mechanisms of estrogen antagonism by nonsteroidal antiestrogens. Mol. Cell. Endocrinol. 1982; 25: 5-23.
16. Charlier C, Chariot A, Antoine N, Merville PM, Gielen J, Castronovo V. Tamoxifen and its active metabolite inhibit growth of estrogen receptor negative MDA-MB-435 cells. Biochem. Phamacol. 1995; 49: 351-8.
17. Hoelting T, Sieperstein AE, Duh Q, Clark OH. Tamoxifen inhibits growth, migration and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo. J. Clin. Endocrinol. Metab. 1995; 80: 308-13.
18. Lointier P, Wildrick DM, Boman BM. Growth effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa. Anticancer Res. 1992; 12: 1523-6.
19. Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Brand M, Fazio VW. The effect of tamoxifen and feretinimide on human colorectal cancer cell lines in vitro. Anticancer Res. 1994; 14: 2005-10.
20. Werner A, Bender E, Mahaffey W et al. Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon. Anticancer Drugs 1996; 7: 307-11.
21. 1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol. 1983; 19: 615-21.
22. Osborne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983; 43: 3583-5.
23. Lykkesfeldt AE, Larsen JK, Christensen IJ, Briand P. Effects of the antiestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. Br. J. Cancer 1984; 49: 717-22.
24. Sakaria JN, Gibson DFC, Jordan VC et al. Tamoxifen increases the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Res. 1993; 53: 4413-17.
25. King CM. Tamoxifen and the induction of cancer. Carcinogenesis 1995; 16: 1449-54.
26. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 1993; 53: 3919-24.
27. Carthew P, Rich KJ, Martin EA et al. DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumour formation. Carcinogenesis 1995; 16: 1299-304.
28. Tucker MJ, Adams HK, Patterson JS. Tamoxifen. In: Laurence DR, McLean AEM, Weatherall M, eds. Safety testing of new drugs. New York: Academic Press, 1984; 125-61.
29. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995; 16: 1651-4.
30. Jiang S, Shyu R, Yeh M, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J. Hepatol. 1995; 23: 712-19.
31. Engstrom PF, Levin B, Moerte CG, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 1990; 65: 2641-3.
32. Mullauer L, Kraupp G, Bursch W, Herman SR. Transforming growth factor beta 1 induced cell death in preneoplastic foci of rat liver and sensitisation by the antiestrogen tamoxifen. Hepatology 1996; 23: 840-7.
33. Wiseman H. Tamoxifen: New membrane mediated mechanism of action and therapeutic advances. Trends Pharmacol. Sci. 1994; 15: 83-9.
34. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen dependent and independent human breast cancer cells. Ann. Surg. Oncol. 1995; 2: 238-45.
35. TakahashiY, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res. 1995; 55: 3964-8.
36. Kitadai Y, Bucana CD, Ellis LM et al. In situ mRNA hybridisation techniques for analysis of metastasis related genes in human colon carcinoma cells. Am. J. Pathol. 1995; 147: 1238-47.